STAT3 INTRINSIC Tumor / fibrotic cell EXTRINSIC Immune cell
2 Clinical STAT3 programs
TTI-101 · TTI-109
Oral STAT3 inhibitors

Oral medicines
for a target once
thought undruggable.

Where cancer, fibrosis & chronic
inflammation converge.

STAT3 TTI-101 SHARED NODE Inhibited directly INTRINSIC Tumor / fibrotic cell EXTRINSIC Immune cell
9.4% Fibrosis-score decrease, wk 12
vs 2.4% on placebo
TTI-101 · Clinical evidence

Fibrosis score
improvement in
IPF at week 12.

Phase 2 REVERT IPF, per company disclosures.

ACTIVE TTI-101 P STAT3 TTI-109 Phosphate prodrug TARGET ENGAGEMENT Confirmed in Phase 1
<2 hrs TTI-109 prodrug
conversion to active drug
Next-gen prodrug · TTI-109

TTI-101-equivalent
exposure, improved
tolerability.

TTI-109 diarrhea events avg. 0.46 days
vs 3.35 for TTI-101.

REVERT IPF Phase 2 data TTI-109 Phase 1 complete PHASE 2 HCC NCT05440708
H2 2026 Topline Phase 2 HCC
data expected
Catalyst · Illustrative financials

Next up: topline
Phase 2 data
in HCC.

$25.0M cash & short-term investments, Mar 31, 2026.

tvardiTherapeutics
INVESTOR RELATIONS · Nasdaq: TVRD
HCC · IPF Lead indications
Orphan + Fast Track FDA designations, HCC
You're subscribed. Watch your inbox.

By subscribing, you consent to receive investor-related emails from Tvardi Therapeutics, Inc. You can unsubscribe at any time.

Forward-looking statements · see SEC filings for risks